(Press-News.org) DURHAM, N.C. -- A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of The Journal of the American Medical Association.
Bristol-Myers Squibb funded the trial of the combination of three drugs -- daclatasvir, asunaprevir, and beclabuvir. None of the three drugs are FDA-approved, but daclatasvir is currently under review by the FDA. Duke Medicine researchers collaborated on the design and analysis of the trial and authored the findings.
The trial recruited patients with hepatitis C-related cirrhosis, or scarring of the liver, 112 of whom had not previously been treated for hepatitis C, and 90 who had previous unsuccessful therapies. For those with past failed therapies and potential resistance, the drugs were slightly less successful, eliminating the virus in 87 percent.
However, for those with past failed therapies, incorporating a fourth drug, ribavirin, appeared to enhance results. Ribavirin is a commonly used hepatitis C treatment. When added to the investigational regimen, success rates in previously treated patients reached 93 percent -- on par with those receiving treatment for the first time.
No vaccine has been developed to protect patients from the hepatitis C virus, which is spread through blood and can lead to liver failure and death if untreated. Most who are infected don't know they have the disease until they have symptoms and have already sustained liver damage, said Andrew Muir, M.D., M.H.S., chief of the division of gastroenterology at Duke and the study's lead author. For this reason, Americans born between 1945 and 1965 -- baby boomers -- should automatically be tested, he urged.
For most of the past 20 years, therapies for hepatitis C relied on interferon drugs, which require regular injections for as long as one year and trigger miserable, flu-like side effects that prompt many patients to quit the regimen. Some patients aren't eligible for this treatment if they have anemia, low platelets or other conditions, Muir said.
"Those with more advanced disease were unlikely to tolerate interferons, and many patients would decide against even getting treatment," Muir said. "For those who could tolerate it, it was only moderately effective."
Since late 2013, several drug companies have released new, interferon-free regimens. In many cases, these have proven to be more effective than previous treatments.
"The development of interferon-free treatments has been a tremendous step forward in the standard of care," Muir said. "These drugs are highly effective and well-tolerated by patients at all stages of liver disease."
The trial was conducted between December 2013 and September 2014 at nearly 50 sites across the United States, Canada, France, and Australia. All patients were infected with genotype 1 hepatitis, a common strain of the C virus in North America, Western Europe and Australia.
The drugs had minimal side effects for most participants. Nine patients experienced serious adverse events three of which were considered related to treatment, the study states.
Among the study's limitations were the absence of a placebo group that could pinpoint the sources of side effects, and a lack of racial diversity, with 88 percent white participants. The study also did not statistically distinguish the impact of the addition of ribavirin to some participants' daily regimen.
INFORMATION:
In addition to Muir, study authors include Fred Poordad; Jacob Lalezari; Gregory Everson; Gregory J. Dore; Robert Herring; Aasim Sheikh; Paul Kwo; Christophe Hézode; Paul J. Pockros; Albert Tran; Joseph Yozviak; Nancy Reau; Alnoor Ramji; Katherine Stuart; Alexander J. Thompson; John Vierling; Bradley Freilich; James Cooper; Wayne Ghesquiere; Rong Yang; Fiona McPhee; Eric A. Hughes; E. Scott Swenson; and Philip D. Yin.
Bristol-Myers Squibb sponsored the study. Muir received grant funding from Bristol-Myers Squibb during the conduct of the trial, as well as grant funding and personal fees from AbbVie, Achillion, Bristol-Myers Squibb, Gilead, and Merck, personal fees from Theravance, and grant funding from Roche outside of the work submitted for this JAMA article.
In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of the direct-acting-antiviral drugs daclatasvir, asunaprevir, and beclabuvir.
Current estimates indicate that 130 million to 150 million people worldwide are chronically infected with HCV, resulting in up to 350,000 deaths per year. Of the 7 HCV genotypes identified, genotype 1 is the most prevalent worldwide, accounting for ...
Among patients with Clostridium difficile infection (CDI) who recovered following standard treatment with the antibiotics metronidazole or vancomycin, oral administration of spores of a strain of C difficile that does not produce toxins colonized the gastrointestinal tract and significantly reduced CDI recurrence, according to a study in the May 5 issue of JAMA.
C difficile is the cause of one of the most common and deadly health care-associated infections, linked to 29,000 U.S. deaths each year. Rates of CDI remain at unprecedented high levels in U.S. hospitals. Clinical ...
In what is a major step towards the prevention of recurring bouts of Clostridium difficile (Cdiff) infection, an international team led by Dale Gerding, MD, Hines Veterans Administration (VA) research physician and professor of Medicine at Loyola University Chicago Stritch School of Medicine, has shown that giving spores of non-toxic Cdiff by mouth is effective in stopping repeated bouts of Cdiff infection which occurs in 25-30 percent of patients who suffer an initial episode of diarrhea or colitis. The study is published in the May 5 issue of the Journal of American ...
For the first time, scientists have imaged thunder, visually capturing the sound waves created by artificially triggered lightning. Researchers from Southwest Research Institute (SwRI) are presenting the first images at a joint meeting of American and Canadian geophysical societies in Montreal, Canada, May 3-7.
"Lightning strikes the Earth more than 4 million times a day, yet the physics behind this violent process remain poorly understood," said Dr. Maher A. Dayeh, a research scientist in the SwRI Space Science and Engineering Division. "While we understand the general ...
Employing online training programs to teach psychotherapists how to use newer evidence-based treatments can be as successful as in-person instruction, according to a new RAND Corporation study.
Psychotherapy treatments can lag years behind what research has shown to be effective because there simply are not enough clinicians trained in new methods. That means that many people with mental health disorders are not getting the most effective nonpharmacological treatments, RAND researchers say.
For one such treatment, Interpersonal and Social Rhythm Therapy to treat bipolar ...
Tropical Storm Noul is still threatening Yap Island located in the Caroline Islands of the western Pacific Ocean, and a part of the Federated States of Micronesia. Micronesia has posted a typhoon warning for the tiny island. The storm is currently 22 miles south-southwest of Ulithi (one of the outer islands of the State of Yap) and is moving west at 2 knots per hour. Maximum sustained winds for the storm is 55 knots gusting to 70 knots and maximum wave height is 20 feet.
Noul is moving to the west and is expected to veer west northwest and later to the northwest. ...
After gobbling the fourth Oreo in a row while bathed in refrigerator light, have you ever thought, "That wasn't enough," and then proceeded to search for something more?
Researchers at BYU have shed new light on why you, your friends, neighbors and most everyone you know tend to snack at night: some areas of the brain don't get the same "food high" in the evening.
In a newly published study, exercise sciences professors and a neuroscientist at BYU used MRI to measure how people's brains respond to high- and low-calorie food images at different times of the day. The ...
Anxiety disorders affect approximately one in six adult Americans, according to the National Institute of Mental Health. The most well-known of these include panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, and social anxiety disorder. But what of brief bouts of anxiety caused by stressful social situations?
A new study by Tel Aviv University researchers, published recently in the Journal of Oral Rehabilitation, finds that anxiety experienced in social circumstances elevates the risk of bruxism - teeth grinding which causes tooth wear and ...
BUFFALO, N.Y. -- Cells that relay information from the ear to the brain can change in significant ways in response to the noise level in the environment.
That's one major finding of a study out today in the Early Edition of the Proceedings of the National Academy of Sciences.
Expose the cells to loud sounds for a prolonged period of time, and they alter their behavior and even their structure in a manner that may aid hearing in the midst of noise. End the ruckus, and the cells change again to accommodate for quieter environs.
"The brain is amazingly adaptable: The ...
A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.
"These medications have to be dosed in a careful way," says senior investigator Adam Kaplin, M.D., Ph.D., an assistant professor of psychiatry and neurology at the Johns Hopkins University School of Medicine. ...
